Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease.
Mannino D, Weng S, Germain G, Boudreau J, Tardif-Samson A, Forero-Schwanhaeuser S, Laliberté F, Gravelle P, Compton CH, Noorduyn SG, Paczkowski R. Mannino D, et al. Among authors: tardif samson a. Adv Ther. 2024 Dec 28. doi: 10.1007/s12325-024-03088-1. Online ahead of print. Adv Ther. 2024. PMID: 39731707
Identification of cytokine release syndrome and indicators of severity in retrospective databases among patients receiving immunotherapy.
Huntington SF, Lin D, Lafeuille MH, Thompson-Leduc P, Shah A, Kim N, Hester L, Tardif-Samson A, Moore B, Fowler J, Marshall A, Zhang X, Gifkins D, Wu B. Huntington SF, et al. Among authors: tardif samson a. Pharmacol Res Perspect. 2024 Dec;12(6):e70024. doi: 10.1002/prp2.70024. Pharmacol Res Perspect. 2024. PMID: 39487576 Free PMC article.
Comparison of Time to Next Treatment or Death Between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant-Ineligible Patients With Multiple Myeloma.
Hansen DK, Gautam S, Lafeuille MH, Rossi C, Moore B, Tardif-Samson A, Thompson-Leduc P, Fu AZ, Cortoos A, Kaila S, Fonseca R. Hansen DK, et al. Among authors: tardif samson a. Cancer Med. 2024 Nov;13(21):e70308. doi: 10.1002/cam4.70308. Cancer Med. 2024. PMID: 39486091 Free PMC article.
Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer.
Gaylis FD, Emond B, Manceur AM, Tardif-Samson A, Morrison L, Pilon D, Lefebvre P, Ellis LA, Balaji H, Ireland A. Gaylis FD, et al. Among authors: tardif samson a. J Health Econ Outcomes Res. 2024 Oct 28;11(2):109-117. doi: 10.36469/001c.124208. eCollection 2024. J Health Econ Outcomes Res. 2024. PMID: 39479557 Free PMC article.
Non-Medical Switching or Discontinuation Patterns among Patients with Non-Valvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States: A Claims-Based Analysis.
Ingham M, Romdhani H, Patel A, Ashton V, Caron-Lapointe G, Tardif-Samson A, Lefebvre P, Lafeuille MH. Ingham M, et al. Among authors: tardif samson a. J Mark Access Health Policy. 2024 Sep 2;12(3):252-263. doi: 10.3390/jmahp12030020. eCollection 2024 Sep. J Mark Access Health Policy. 2024. PMID: 39315122 Free PMC article.